> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Arizona Sues L’Oréal Over Alleged Hair-Relaxer Cancer Warnings
- URL: https://www.theamericanquorum.com/state-news-arizona-2026-09-16-a/
- Published: 2026-09-16T04:26:41.000Z
- Updated: 2026-09-16T04:26:41.000Z
- Description: Arizona’s attorney general alleges L’Oréal marketed chemical hair relaxers without adequate cancer-risk disclosures. The company denies the claims, and the cited research shows association, not causation.
- Author: News Desk
- Tags: State News, Arizona

Arizona has filed a consumer-fraud lawsuit alleging that L’Oréal and related companies marketed chemical hair relaxers without adequately disclosing research linking frequent use to elevated cancer risks. The case, announced September 11, seeks penalties, damages and restrictions on continued sales without warnings. The allegations have not been proven in court.

The [Attorney General’s Office said](https://www.azag.gov/press-release/attorney-general-mayes-files-consumer-fraud-lawsuit-against-loreal-usa?ref=theamericanquorum.com) its complaint names L’Oréal USA, its parent company and Softsheen. State lawyers allege that products aimed primarily at Black women—and, in some instances, children—were advertised and sold without adequate disclosure of potential risks including uterine and ovarian cancers.

The [state-court complaint](https://mcusercontent.com/cc1fad182b6d6f8b1e352e206/files/3f20d793-8b23-b96f-0cf3-2d4f453d84ed/2026%5F09%5F10%5FL%5F039%5FOreal%5FComplaint.01.pdf?ref=theamericanquorum.com) frames the alleged omissions as violations of Arizona’s Consumer Fraud Act. The filing asks the court to award restitution and civil penalties and to require warnings if the products remain on sale. Those requests describe the state’s position; they are not findings by the court.

L’Oréal disputes the case. A company spokesperson told [Reuters](https://www.reuters.com/legal/litigation/arizona-accuses-loreal-concealing-cancer-risks-linked-hair-relaxers-2026-09-11/?ref=theamericanquorum.com) that the company is confident in the safety of its products and considers the claims without legal or scientific merit. Reuters reported that this is the first state-level enforcement action over the alleged hair-relaxer cancer risks and that more than 12,000 private cases have been consolidated in federal multidistrict litigation.

The scientific evidence requires careful wording. A [2022 National Institutes of Health study](https://www.niehs.nih.gov/newsreleases/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk?ref=theamericanquorum.com) followed 33,947 women for nearly 11 years. Women who reported using chemical straightening products more than four times in the previous year were more than twice as likely to develop uterine cancer as nonusers. Researchers estimated risk by age 70 at 4.05 percent for frequent users, compared with 1.64 percent for women who reported never using straighteners.

That study found an association; it did not establish that a particular brand or ingredient caused an individual cancer. Researchers did not collect the brands or ingredients used, and the institute said more research was needed to confirm the finding and identify chemicals that may drive the observed relationship. L’Oréal has emphasized that limitation in rejecting the lawsuits’ causal claims.

The distinction between relative and absolute risk is also important. “More than twice as likely” can sound conclusive, but the study’s estimated absolute difference was about 2.4 percentage points by age 70\. Individual risk can vary with age, medical history and other exposures, none of which the lawsuit resolves for a particular consumer.

For Arizona consumers, the immediate change is legal scrutiny, not a court-ordered recall. Products remain subject to existing federal cosmetics rules unless a regulator or judge orders otherwise. Anyone considering a relaxer can review ingredient and warning information, discuss personal risk factors with a medical professional and report suspected deceptive practices through the Attorney General’s consumer-complaint system.

The next steps will be the defendants’ formal responses and the court’s decisions on whether the state’s claims can proceed. The case will turn not only on the epidemiological research, but also on what the companies knew, what they communicated to consumers and what disclosures state consumer-protection law required.